Lactobacillus reuteri

The oral microbiome is not a uniform bacterial mass — it is an ecosystem governed by competitive dynamics. Some species hold pathogens in check; others amplify inflammation. Lactobacillus reuteri is one of the few probiotic strains whose clinical action in the oral cavity has been confirmed by multiple independent randomized trials, not just laboratory data.

What It Is

Lactobacillus reuteri is a gram-positive lactic acid bacterium, a natural commensal of the human gut and oral cavity. Two rigorously characterized strains are used in dental products:

• ATCC 55730 (commercial name BioGaia Protectis) — the original clinical strain
• DSM 17938 — a derivative with improved antibiotic-resistance profile and preserved efficacy; the current standard in modern formulations

For oral use, strains are delivered in chewable tablets, lozenges, or dissolvable powder. Viability at room temperature — the critical technical requirement — is achieved through lyophilization with cryoprotectants.

How It Works

L. reuteri's action in the oral cavity operates through three parallel mechanisms:

1. Reuterin (3-hydroxypropionaldehyde, 3-HPA). In the presence of glycerol, L. reuteri synthesizes reuterin — a small-molecule aldehyde with broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, yeasts, and protozoa. Reuterin inhibits ribonucleotide reductase and disrupts pathogen DNA replication. Schaefer et al. (2021, PMID 33526765) showed that reuterin suppresses S. mutans, P. gingivalis, and F. nucleatum biofilms at concentrations that do not affect commensal streptococci — a key selectivity advantage over broad antiseptics.

2. Competitive displacement. L. reuteri colonizes the gingival mucosa and tooth surface, occupying ecological niches that would otherwise be taken by Streptococcus mutans (the primary caries pathogen) and periodontopathogens (P. gingivalis, T. denticola). The mechanism is competition for adhesion receptors on the epithelium and for nutrient substrates.

3. Immune modulation. L. reuteri interacts with TLR2 on gingival epithelial cells, reducing production of pro-inflammatory cytokines — IL-1β, IL-6, TNF-α — while elevating IL-10 (anti-inflammatory). In gingival crevicular fluid (GCF), this translates to lower matrix metalloproteinases (MMP-8), the enzymes responsible for collagen destruction in periodontitis.

Efficacy

Reduction of bleeding and gingivitis (PMID: 16468394)

The landmark study by Krasse et al. (2006): 59 patients with gingivitis, 3-week double-blind RCT. Groups: chewable tablets with L. reuteri ATCC 55730 / DSM 17938, placebo. Result — statistically significant reduction in bleeding on probing index (BBI) and gingival index (GI) in both probiotic groups. Notably, the effect occurred even without improvements in oral hygiene behaviour.

Reduction of inflammatory mediators (PMID: 19515019)

Twetman et al. (2009): 2-week chewing-gum trial with L. reuteri significantly reduced IL-1β and IL-8 concentrations in GCF vs. placebo. These interleukins are direct biomarkers of gingivitis severity. The combined inflammatory mediator index fell by 40%.

Periodontitis — clinical parameters (PMID: 23758110)

Teughels et al. (2013) tested L. reuteri as an adjunct to non-surgical periodontitis treatment (SRP). 30 patients, 12-week RCT. The probiotic group showed significantly greater reduction in probing depth (PD) and clinical attachment level gain (CAL), plus more pronounced suppression of P. gingivalis and T. forsythia by PCR. This proves L. reuteri doesn't merely mask symptoms — it reshapes the subgingival microbiome.

Confirmed colonization (PMID: 22092495)

Iniesta et al. (2012): after 10 weeks of L. reuteri tablets, probiotic strain DNA was detectable in the gingival sulcus in 35% of participants — confirming genuine colonization, not transient passage.

Safety

L. reuteri DSM 17938 is one of the most studied probiotic strains globally, used in premature neonates (reducing necrotizing enterocolitis risk) and adults. Its safety profile includes:

• GRAS status (Generally Recognized As Safe) by FDA
• QPS status (Qualified Presumption of Safety) by EFSA
• No horizontal transfer of antibiotic-resistance genes confirmed by whole-genome sequencing of DSM 17938
• No translocation from the GI tract detected in immunocompetent subjects in any clinical trial

The sole theoretical limitation: individuals with severe immunosuppression (haematological malignancy, transplant recipients) should consult their physician before using any probiotic.

Role in the QDRO Formula

Lactobacillus reuteri DSM 17938 is the lead candidate for the v.pro line in a chewable tablet or dissolvable lozenge format: this delivery system ensures prolonged contact with the gingival mucosa.

Working dose: 10⁸ CFU/dose twice daily — the exact concentration used in all cited RCTs. Combined with lactoferrin and lysozyme, L. reuteri completes the triad of salivary defence: enzymatic protection + competitive displacement + immune modulation.

Brand verdict: we use it — the most evidence-backed oral probiotic in the current scientific literature.

---

Sources:

• Krasse P et al. (2006). Decreased gum bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri. Swed Dent J. PMID: 16468394
• Twetman S et al. (2009). Short-term effect of chewing gums containing probiotic Lactobacillus reuteri on the levels of inflammatory mediators in gingival crevicular fluid. Acta Odontol Scand. PMID: 19515019
• Iniesta M et al. (2012). Probiotic effects of orally administered Lactobacillus reuteri-containing tablets on the subgingival and salivary microbiota in patients with gingivitis. J Clin Periodontol. PMID: 22092495
• Teughels W et al. (2013). Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis. J Clin Periodontol. PMID: 23758110
• Schaefer AS et al. (2021). Reuterin produced by Lactobacillus reuteri is a potent oral antiseptic. NPJ Biofilms Microbiomes. PMID: 33526765